Catalyst

Slingshot members are tracking this event:

First Study Initiated to Evaluate the Effect of Ofev Treatment on Biomarkers that may Predict IPF Progression

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
Boehringer Ingelheim

100%

Additional Information

Additional Relevant Details
INMARK™ study will investigate the effect of OFEV on the rate of change of ECM turnover biomarkers compared to placebo in patients with IPF. Two thirds of patients will be treated with placebo for the first 12 weeks of the trial; one third of the patients will receive treatment with nintedanib (150 mg twice daily). Following the 12 week placebo controlled period, all patients in the trial will continue further treatment with nintedanib for 40 weeks. This will allow active treatment for patients previously on placebo. The study aims to include 350 patients across Australia, Asia, Europe and North America.
http://www.prnewswir...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Inmark, Ofev, Biomarkers, Ipf Progression, Nintedanib, Ipf Lungs, Progressive Scarring, Lung Function, Idiopathic Pulmonary Fibrosis